Skip to main content
. 2015 Sep 25;76(5):969–975. doi: 10.1007/s00280-015-2870-0

Fig. 1.

Fig. 1

Schema showing 5 phases of study CA184-202 and the tumor assessment schedule. DTIC dacarbazine; IPI ipilimumab; PD progressive disease; q3w every 3 weeks; q6w every 6 weeks; q12w every 12 weeks; TA tumor assessment; W week